Overview

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoGen, Inc.